Institution identification

PURI

https://redirect.ema.europa.eu/resource/26905

Institution ID

26905

Institution full name and acronym

Leibniz Institute for Prevention Research and Epidemiology - BIPS

Institution countries

Germany

Type of institution

Not-for-profit

Institution website

ENCePP partner

Yes
Institution description
BIPS is one of the oldest epidemiological institutes in Germany. It was founded in 1981 under the name of "Bremen Institute for Prevention Research and Social Medicine" as a research institute of the Society for the Promotion of Scientific Research in the Free Hanseatic City of Bremen (Verein zur Foerderung der wissenschaftlichen Forschung in der Freien Hansestadt Bremen e.V.). As of January 1, 2013, the institute is a full member of the Leibniz Association and operates under the new name Leibniz Institute for Prevention Research and Epidemiology - BIPS. BIPS develops effective strategies for the prevention of chronic, non-communicable diseases. Supporting a healthy life-course early on is the primary goal. The research focus is therefore on factors beyond individual diseases, such as lifestyle and environment, biological and social factors, as well as early detection and drug safety. BIPS' research spectrum covers methodological development, the identification of the causes of diseases, and intervention and implementation research. BIPS also offers information to politicians and the general population and provide academic qualification to young scientists. BIPS thus covers the entire cycle of epidemiological research.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

A non-interventional post-authorisation safety study to investigate the risk of mortality in multiple sclerosis patients treated with alemtuzumab (LEMTRADA®) relative to comparable multiple sclerosis patients using other disease modifying therapies: a cohort study
A pharmacoepidemiological study of Rivaroxaban use and potential adverse outcomes in routine clinical pratice in Germany
A Retrospective Cohort Study to Assess Drug Utilisation and Long-Term Safety of Galcanezumab in European Patients in the Course of Routine Clinical Care (I5Q-MC-B002)
ACCESS template protocol for safety of COVID-19 vaccines
Adherence, persistence and switching patterns – once- and twice-daily direct oral anticoagulants (QD versus BID DOACs)
Burden of Herpes Zoster in selected immunocompromised populations in the German Pharmacoepidemiological Research Database (GePaRD)
Cilostazol Drug Utilisation Study
Cohort Study of the Relative Incidence of Major Cardiovascular Events Among Patients Initiating Prucalopride Versus a Matched Comparator Cohort
CONSIGN study: COVID-19 infection and medicines in pregnancy - a multinational registry based study
Database study of lenalidomide (Revlimid®) in Germany: Monitoring off-label use
Database Study of Thalidomide (Thalidomide Celgene®) in Germany: Monitoring Off-Label Use
Demonstrating solutions for studying intermittent medication exposures in diseases with episodic manifestations during pregnancy: application to medication for migraine in pregnancy
Drug utilisation study of Radium 223 under routine clinical practice in Europe (DIRECT)
Dulaglutide Modified-Prescription-Event Monitoring Study and network database study: a multi-database collaborative research program of observational studies to monitor the utilisation and safety of dulaglutide in the EU
Estimation of Background Incidence Rates of Guillain-Barré Syndrome in Germany in the years 2007-2009 (BIGS)
EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU ADR ALLIANCE
EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO ADHERENCE TO THE RISK MINIMIZATION MEASURES FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE
European non-interventional post-authorization safety study related to serious cardiovascular events of myocardial infarction and stroke, and all-cause mortality for romosozumab by the EU-ADR Alliance
Exposure to SSRI/SNRI and depression in pregnancy and long-term childhood outcomes: the effect of modifying factors
Extrapyramidal symptoms in patients treated with Abilify Maintena®: Cohort study with a 2-year follow-up using European automated healthcare databases
Intravenous Iron Postauthorisation Safety Study (PASS): Evaluation of the Risk of Severe Hypersensitivity Reactions
Long-Term Post-Marketing Observational Study of the Safety of Roflumilast
Off-label use of neuroleptics and antidepressants and risks of psychostimulant use in ADHD patients during childhood and adolescents (OLUNAR)
Pharmacoepidemiological Safety Study of Neuroleptics and Antidepressants in the Area of Geriatric Psychiatrics (PhaSiNAg)
Post-Authorisation Safety Study of Agomelatine and the Risk of Hospitalisation for Acute Liver Injury
Post-authorisation Safety Study of Tralokinumab Use in Pregnancy: An Observational Study Based on Electronic Healthcare Data
Risk of Febrile Convulsions after 1st dose MMRV vaccination in comparison to MMR and MMR+V vaccination (MMRV 1st dose)
Risk of Febrile Convulsions after a Second Immunization against Measles, Mumps and Rubella with MMRV as compared to MMR or MMR+V (MMRV 2nd dose)
Risk of Venous Thromboembolism and All-Cause Mortality in Cancer Patients Treated with Epoetins either with or without Transfusions versus Cancer Patients Treated with Transfusions alone
Safety Evaluation of Adverse Reactions in Diabetes - Comparative studies (SAFEGUARD)
Safety Evaluation of Adverse Reactions in Diabetes - Drug utilisation studies (SAFEGUARD)
Second primary cancers in patients with castration resistant prostate cancer (BOCARP)
The BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study in electronic healthcare databases
The risk of ischemic cardiovascular events associated with oxycodone/naloxone use
Thromboembolic Risk in Patients with Chronic Kidney Disease Treated receiving Epoetin zeta or other Erythropoietin Stimulating Agents – the BIPS study
VALIDATION STUDY PROTOCOL (OP0007) FOR THE EUROPEAN NON-INTERVENTIONAL POST- AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS CARDIOVASCULAR EVENTS OF MYOCARDIAL INFARCTION AND STROKE AND ALL-CAUSE MORTALITY FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0004) AND EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0006)